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We describe an outbreak of methicillin-resistant Staphylococcus aureus (MRSA) among injection drug users
(IDUs). From August 1994 through December 1999, we registered 31 IDUs with MRSA infections (12 with
soft-tissue infection, 7 with pneumonia [fatal in 1], 7 with endocarditis [fatal in 1], 2 with osteomyelitis, 2
with septic arthritis, and 1 with ulcerative tonsillitis), with a marked increase in the number of IDUs registered
during 1998 and 1999. Of 31 patients, 15 (48%) were infected with human immunodeficiency virus. A point-
prevalence study among IDUs who frequented outpatient facilities in Zurich revealed an MRSA carriage rate
of 10.3% (range, 0%–28.6%) in various facilities. In all but 1 case, pulsed-field gel electrophoresis banding
patterns of isolates obtained from these patients were indistinguishable from isolates of the initial 31 IDUs
registered. Risk factors for MRSA carriage were disability and prior hospitalization in a hospice. In summary,
MRSA became endemic in IDUs in Zurich as a result of the spread of a single clone. This clone caused major
morbidity and was responsible for a lethal outcome in 2 cases.
The prevalence of methicillin-resistant Staphylococcus
aureus (MRSA) in persons in Switzerland is relatively
low, and there is a wide variation in prevalence (range,
0%–21%) between different hospitals in Switzerland
[1]. As in most parts of the world, MRSA transmission
occurs mainly among hospitalized patients. Transmis-
sion of MRSA to the general population may originate
from patients who remain colonized after discharge or
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from health care workers. Transmission in the other
direction is also possible and was reported in 1982 [2].
An epidemic of MRSA infection occurred among users
of parenteral drugs in Detroit. This epidemic originated
in the community, but the pathogen was later found
in several hospitals and nursing homes, and it resulted
in an increase in the rate of nosocomial MRSA
infections.
The number of injection drug users (IDUs) in Zu-
rich, Switzerland is substantial [3]. Many have multiple
contacts with various medical facilities. Infections
caused by S. aureus are common among IDUs [4] and
result in considerable morbidity. In the present study,
we report on the prevalence of MRSA and on an ep-
idemic of MRSA in a cohort of IDUs in Zurich.
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Figure 1. The number of injection drug users (IDUs) with newly de-
tected methicillin-resistant Staphylococcus aureus (MRSA) per year is
shown. Presence of MRSA was detected in clinical specimens, usually
at the time of manifest infection. Cases detected during the prevalence
survey are not included in this figure.
METHODS
Clinical setting and MRSA surveillance. The University
Hospital of Zurich (UHZ) is a 1000-bed hospital that, in ad-
dition to its academic mission to provide tertiary care, provides
primary care to the inhabitants of the Zurich metropolitan area.
Primary care is also provided by 2 city hospitals. These hos-
pitals, as well as the orthopedic university hospital and a hospice
in the downtown area, collaborate closely with the hospital
epidemiology (HE) unit of UHZ and send all MRSA isolates
to the HE laboratory at UHZ. All MRSA cases in the Zurich
area have been prospectively registered since 1993, as part of
the surveillance activities of the HE unit of UHZ. MRSA isolates
are subjected to molecular genotyping. Physicians who take care
of patients infected with MRSA of the genotype responsible for
this outbreak were contacted (see Evolution of MRSA epidemic
section), and the medical records of these patients were re-
viewed retrospectively for demographic and clinical data. Dem-
ographic data included age and sex. Clinical data included the
type of infection and underlying illnesses, including HIV infec-
tion, and the presence and degree of cellular immunodeficiency.
Survey of MRSA prevalence. To determine the prevalence
of MRSA carriage and/or infection among IDUs in the city of
Zurich, we conducted a prospective, clinical-epidemiological
study in July and August 1999. A hospice with a dispensary
(Sune-Egge), a dispensary for the homeless (KFO), a drug re-
habilitation clinic (Frankental), 2 facilities that distribute drugs
and allow injection of drugs under controlled circumstances
(Crossline and Lifeline), and 6 drug-injection facilities were
included. Drug-injection facilities provide a hygienic environ-
ment (including distribution of needles and syringes) in which
IDUs are permitted to inject drugs purchased on the street.
Approximately two-thirds of IDUs agreed to screening of
anterior nares with the use of swabs, to determine nasal carriage
of MRSA. A standardized questionnaire was used to collect
information on sociodemographic factors, type and frequency
of drug use, presence of medical disability, type of interactions
with other IDUs, living conditions (e.g., apartment, shelter, or
homeless), and any hospitalizations that occurred during the
preceding 6 months.
Microbiological studies and genotyping. Nose swabs were
immediately introduced into a transport medium (Stuart me-
dium). Cultures were performed on sheep blood agar and were
incubated for 24 h at 357C. Identification of S. aureus was based
on the morphology of colonies, typical Gram staining, and a
positive result of a catalase test and was confirmed with the
use of Staphaurex (Murex Diagnostics). Antimicrobial suscep-
tibility testing was performed according to the guidelines of the
National Committee for Clinical Laboratory Standards [5], by
means of disk diffusion methodology with Mueller-Hinton agar
(Oxoid) and oxacillin disks (1 mg). The zone-diameter break-
points for isolates susceptible or resistant to oxacillin were >13
mm and <10 mm, respectively. Mupirocin disks (5 mg) were
used to determine susceptibility to this compound. The zone-
diameter breakpoints for isolates susceptible or resistant to mu-
pirocin were >14 mm and <13 mm, respectively [6].
Each MRSA isolate was confirmed with MRSA-Screen
(Denka Seiken), a slide latex agglutination kit for the rapid
detection of penicillin-binding protein 2. PCR analysis of ran-
dom isolates was done to determine the presence of the mecA
gene. Molecular analysis of each isolate was done by pulsed-
field gel electrophoresis (PFGE) with the use of Sma 1 restric-
tion enzyme, by use of a CHEF-DR III system (Bio-Rad). Initial
switch time was 1 s, final switch time was 45 s, and the run
time was 24 h at 6 V/cm. Gels were stained with ethidium
bromide and viewed by ultraviolet transillumination, and the
pattern of restriction fragment bands was interpreted. Isolates
were considered to be the same strain according to the criteria
published by Tenover et al. [7].
Statistical analysis. Categorical variables were analyzed
with Fisher’s exact test. Continuous variables were analyzed
with Student’s t-test. was considered statistically sig-P ! .05
nificant. All tests were 2-sided. Computations were performed
with use of Statview software (version 4.5; Abacus Concepts).
RESULTS
Evolution of MRSA epidemic. From August 1994 through
December 1999, we registered 31 IDUs with MRSA infection.
MRSA isolates were recovered sporadically from IDUs during
1994–1997, whereas a marked increase was noted during
1998–1999 (figure 1). During the same period, the number of
IDUs seen at the involved hospitals did not change significantly
from year to year. Clinically relevant infections that required
hospitalization were noted in all patients (table 1). Of the 31
patients, 15 (48%) were infected with HIV and had various
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Table 1. Clinically relevant infections in patients infected with methicillin-resistant Staphylococcus aureus.
Type of infection
No. of patients
(n p 31)
Patient age,
mean y (range)
Sex of patients,
no. of males:no.
of females Comment
Wound or soft-tissue infection 12 36.0 (26–42) 9:3 Complications of drug injections
Pneumonia 7 35.3 (28–43) 4:3 2 patients with sepsis, 1 with
empyema, 1 with fatal
outcome
Endocarditis 7 41.1 (27–58) 5:2 1 patient with fatal outcome
Osteomyelitis 2 34.5 (30–39) 1:1 Vertebral column and pelvis
were affected
Septic arthritis 2 34.5 (31–38) 1:1 Knee and hip joint were
involved
Ulcerative tonsillitis 1 30 0:1 Unilateral tonsillitis
degrees of cellular immunodeficiency, with CD41 lymphocyte
counts ranging from 53/mL to 769/mL.
After the discovery of the outbreak, a hospice for IDUs
(Sune-Egge) in downtown Zurich was recognized as a potential
site for the spread of MRSA. Screening of all hospice patients
in October 1998 revealed nasal carriage of MRSA in 12.5% (3
of 24 patients).
Susceptibility and genotype of MRSA isolates. All MRSA
isolates were susceptible to mupirocin, clindamycin, and gen-
tamicin or netilmicin; 30 of 31 isolates were susceptible to
rifampin; and 29 of 31 isolates were susceptible to ciprofloxacin.
However, 24 of 31 were resistant to cotrimoxazole. All 31 iso-
lates had identical banding patterns by PFGE.
Point-prevalence study. A point-prevalence survey per-
formed from July through August 1999 involved a total of 280
swab specimens obtained from the anterior nares of 224 IDUs
and 56 health care workers at the 12 study locations. S. aureus
was identified in 94 (33.6%) of these specimens. These isolates
originated from 79 IDUs (carriage rate, 35.3%) and 15 health
care workers (carriage rate, 26.8%). None of the isolates re-
covered from health care workers was resistant to methicillin.
Of the 224 IDUs, 23 (10.3%) had nasal cultures that were
positive for MRSA, which accounted for 29.1% of S. aureus
isolates (23 of 79). A single isolate was resistant to mupirocin
on Mueller-Hinton agar.
The prevalence of MRSA colonization varied markedly be-
tween the different facilities. Prevalence was 23.3% in the hos-
pice and 28.6% in 1 of the drug-injection facilities. In other
facilities, prevalence varied from 0% to 15%.
Transmission of the outbreak strain. Molecular genotyp-
ing by PFGE of MRSA isolates revealed that 22 isolates belonged
to a single clone and that the banding pattern was indistin-
guishable from the pattern recognized during the initial epi-
demic. A different pattern was found for only 1 IDU from 1
of the drug-injection facilities. MRSA that belonged to the same
genotype was isolated from the wound of a patient who had
been hospitalized in the radio-oncology unit of the University
Hospital of Zurich at the same time as one of the patients who
belonged to the cohort of IDUs. Although no epidemiological
links could be established between these 2 patients, nosocomial
transmission of MRSA from the IDU to the second patient on
the radio-oncology unit can be assumed on the basis of the
temporal association of the hospital stays of these patients.
Before the current epidemic, this strain had not been detected
in other patients hospitalized at any of the hospitals in the
greater Zurich area.
Risk factors for colonization. Of all the factors considered
in the analysis of risk factors for colonization (table 2), pension
for disability and prior hospitalization at the hospice were sig-
nificantly more common among MRSA carriers.
DISCUSSION
This study shows that a single clone of MRSA is currently
endemic in IDUs in Zurich, that this clone is responsible for
an ongoing outbreak, and that it may spread secondarily to
other patient groups. This outbreak poses serious problems for
various health care facilities in the Zurich metropolitan area.
The association between MRSA and injection drug use is not
new. In 1982, Saravolatz et al. [4] reported 165 patients with
infections caused by community-acquired MRSA at Henry Ford
Hospital (Detroit). The proportion of community-acquired S.
aureus infections resistant to methicillin at Henry Ford Hospital
rose from 3% in March 1980 to 38% in September 1981. In-
jection drug use was associated with the development of this
infection [4]. Ten years later, MRSA accounted for 47% of the
isolates obtained from 101 IDUs with S. aureus infection at the
same tertiary-care hospital [8]. In Spain, a country with a high
rate of MRSA in hospitals [9], MRSA was not endemic in IDUs
in 1992. Rubio et al. [10] analyzed 311 episodes of S. aureus
bacteremia during a 4-year period. Endocarditis in IDUs was
responsible for 53 of these bacteremia episodes. However, in
these patients, MRSA was rare.
Nasal colonization with S. aureus is epidemiologically linked
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Table 2. Characteristics of injection drug users (IDUs) colonized with meth-
icillin-resistant Staphylococcus aureus (MRSA) versus those of IDUs not col-
onized with MRSA.
Characteristic
IDUs colonized
with MRSA
(n p 23)
IDUs not colonized
with MRSA
(n p 201) P
Sex
Male 15/23 (65) 156/197 (79) .18
Female 8/23 (35) 41/197 (21)
Age mean y 5 SD 36 5 4 33 5 9 .125
Drug use
Within a group 7/16 (44) 37/155 (24) .13
Usually alone 9/16 (56) 118/155 (76)
Circumstances of living
Apartment 18/23 (78) 141/201 (70) 1.2
Therapy group 0 13/201 (6.5) 1.2
Shelter 3/23 (13) 19/201 (9.5) 1.2
Homeless 2/23 (9) 28/201 (14) 1.2
Employment status
Regular job 1/23 (4) 28/200 (14) 1.2
Occasional job 2/23 (9) 30/200 (15) 1.2
Unemployed 7/23 (31) 73/200 (36.5) 1.2
Pension for disability 13/23 (56) 69/200 (34.5) .04
No hospitalization during 1999 12/23 (52) 88/177 (49.7) 1.2
Hospitalizations during 1999
University Hospital 4/14 (28) 25/115 (22) 1.2
Waid City Hospital 1/14 (7) 5/115 (4) 1.2
Triemli City Hospital 1/14 (7) 12/115 (10) 1.2
Sune-Egge (Hospice) 8/14 (57) 35/115 (30) .07a
Other 0 38/115 (33) .01
NOTE. Data are n/N (%) of patients, unless otherwise indicated.
a by Pearson’s test.2P p .045 x
to an increased risk of subsequent infection [11, 12]. In IDUs,
it also appears to predispose to infection by providing a res-
ervoir from which the skin is seeded [13]. Frequent needle
injections without proper antiseptic technique provide a portal
of entry [13]. A similar association between nasal carriage and
an increased risk for invasive infections was reported for HIV-
infected patients [14].
We therefore studied the prevalence of nasal MRSA carriage
in a cohort of IDUs in Zurich. The prevalence of MRSA nasal
carriage in our population was 10.3%, and MRSA accounted
for 29.1% of S. aureus isolates. There was a wide range in
prevalence of MRSA among the different facilities (0% in a
suburban facility and up to 28.6% in downtown facilities). The
reason for these differences in prevalence of MRSA is unknown.
It may be speculated that IDUs who frequent a drug-injection
facility in one of the suburbs of Zurich have only rare contacts
with IDUs at facilities in the downtown area.
Studies in other geographic locations showed markedly lower
prevalence rates. From March 1994 through May 1995, Hol-
brook et al. [15] studied 217 current and former drug addicts
who were recruited from a hospital-affiliated methadone-main-
tenance program in the Bronx, New York, for an ongoing lon-
gitudinal study of the natural history of HIV disease. Nasal
cultures were positive for S. aureus for 41% of the subjects.
The antibiotic susceptibility patterns were similar to those of
the isolates obtained from outpatients at the local hospital and
included 2.3% MRSA. No dominant strain was identified by
arbitrarily primed PCR analysis [15]. Dan et al. [16] studied
the carriage of MRSA in nonhospitalized subjects in Israel. In
350 drug users who attended a methadone clinic, the isolation
rate of S. aureus was 9.1% ( ), and only 2 IDUs (0.6%)n p 32
had nasal colonization with MRSA [16]. Genotyping was not
done.
In our study, the high prevalence of MRSA in IDUs was
caused by the local spread of a single clone. This is in contrast
to the findings reported by Layton et al. [17], who described
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the epidemiology of MRSA at a university hospital in New
Haven, CT. Among 87 patients with MRSA, 36 had community-
acquired infections, which were associated with injection drug
use in 6 cases. PFGE allowed differentiation of 35 distinct DNA
patterns; heterogeneity was seen among both nosocomial and
community-acquired isolates, with few instances of cross-
transmission.
The mechanism of spread of the epidemic strain among IDUs
in Zurich is unclear. MRSA carriers had a higher rate of hos-
pitalizations in a hospice in downtown Zurich and included
more recipients of pension for disability. This may be inter-
preted as a marker for prolonged drug use. Craven et al. [18]
had previously noted that chronic drug use is a reason for the
use of “shooting galleries” by IDUs. MRSA carriers also had a
higher rate of drug use within a group rather than alone, but
this difference was not statistically significant. Frequent and
close contacts may be a source of person-to-person transmis-
sion of MRSA. For instance, Lindenmayer et al. [19] reported
the transmission of MRSA among healthy participants on a
high school wrestling team.
Furthermore, needle-sharing can facilitate transmission of
an epidemic strain. Craven et al. [18] reported 7 episodes of
MRSA endocarditis. All patients patronized a local “shooting
gallery,” where paraphernalia were provided and drugs were
often administered by a “street doctor.” All isolates were the
same phage type [18]. HIV-infection prevention strategies re-
duced this behavior among drug users. An older study at the
Detroit Medical Center suggested that one brand of heroin
served as a common source [20]. Saravolatz et al. [2] found
that culture results for heroin samples provided by drug users
with MRSA infection were negative, which is consistent with
findings of previous investigators, who were unable to recover
significant pathogens when culturing heroin [21]. Since there
were no significant differences regarding drug-use behavior be-
tween carriers of MRSA and noncarriers in our study popu-
lation, we consider heroin or cocaine to be very unlikely sources
of this outbreak. Given the particular living conditions of many
IDUs, frequent and close social contacts appear to be the most
likely explanation for the observed spread of MRSA in this
cohort.
MRSA is not the only bacterial agent that causes epidemic
outbreaks among IDUs. Recently, an outbreak of a single clone
of nontoxigenic Corynebacterium diphtheriae that caused in-
fections among drug users in Zurich was reported. A total of
38 of 65 patients from whom C. diphtheriae had been isolated
from 1990 through 1996 were IDUs. Skin infections were doc-
umented in 15 patients, respiratory infections in 10, and bac-
teremia in 13 (including 9 patients with endocarditis, 4 of
whom died). The same ribotype of nontoxigenic C. diphtheriae
was found in 31 of the 32 examined isolates associated with
injection drug use [22]. Shekar et al. [23] described an outbreak
of endocarditis caused by Pseudomonas aeruginosa serotype 011
among abusers of pentazocine and tripelennamine in Chicago.
Because IDUs have multiple contacts with various medical
facilities [24], it is important to eradicate MRSA in this pop-
ulation to prevent the spread of MRSA within institutions such
as dispensaries and hospices, as well as the spread to community
and university hospitals. Spread of MRSA into health care fa-
cilities carries the potential for secondary spread to non-IDUs.
This has occurred at least once at the University Hospital of
Zurich, as a result of the current outbreak. Larger outbreaks
that involve transmission of MRSA to hospitalized HIV-infected
patients have been reported from the United Kingdom [25]
and Spain [26].
In summary, we observed a marked increase in MRSA among
IDUs in the Zurich area. This increase was caused by the local
spread of a single clone. The observed MRSA clone caused
significant morbidity in this group of IDUs. MRSA is currently
endemic among IDUs in Zurich. The emergence of MRSA in
IDUs in Zurich poses risks for spread in the inpatient and
outpatient settings, because of the persistence of colonization
that may go unrecognized for a prolonged time.
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